" class="no-js "lang="en-US"> Ron Zwanziger - Medtech Alert
Tuesday, August 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Ron Zwanziger

Ron Zwanziger

About Ron Zwanziger

Strategic visionary and entrepreneur, Ron Zwanziger leads LumiraDx having co-founded the business in 2014. Previously, he built and has been Chairman and CEO of several leading diagnostic companies including Alere, Inverness Medical Technology (right up to its acquisition by Johnson & Johnson in 2001) and MediSense – the first company to launch an electrochemical glucose sector. He currently serves on the Board of Directors of several private companies.

Related Story

COVID-19

 LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System

June 13 2022

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it has […]

COVID-19

 LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking | Pharmtech Focus

LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

May 20 2022

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 Ag Ultra […]